





ON TARGET



QuadraSphere™
Microspheres



DISTAL TARGETING WITH THE
POWER OF CONFORMABILITY




In vivo photomicrograph of QuadraSphere® Microspheres

Courtesy of Dr. Keigo Osuga

TARGETED OCCLUSION

QuadraSphere Q2™ Microspheres demonstrated a median occlusion of 78 μm, a statistically significant difference compared to larger sizes of QuadraSphere.*

Median Diameter of Occluded Arteries



QuadraSphere Q2 Microspheres are sized for intratumoral targeting and conform to the vessel lumen for complete occlusion:

- Decreasing the risk of vessel recanalization¹
- Enabling greater tumor necrosis^{2,3}
- Providing optimal contact between the vessel wall and microsphere surface^{1,4}
- Enhancing the embolic effect, reducing the amount of product needed to reach embolization endpoint¹

Q2 PRODUCT INFORMATION

Dry Size (μm)	Hydrated Size (μm)	Catheter Size ID	Color Code	Order Number
20-40	80-160	≥ 0.020"	● Gray	V125QS

QuadraSphere Q2 Microspheres are packaged dry; 25mg per vial; 1 vial per box. Must be reconstituted before use.

Reimbursement Service:
Institute for Quality
Resource Management

Phone: (888) 447-1211
Email: embo@IQRM.info

*Swine liver embolization model study performed for Merit Medical. QuadraSphere Microspheres prepared in 50/50 mixture of saline/contrast.

References

1. Bilbao JI, de Luis E, Garcia de Jalón JA, et al. Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. J Vasc Interv Radiol 2008 Nov;19(11):1625-38.
2. Lee KH, Liapi E, Vossen JA, et al. Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol 2008 Oct;19(10):1490-6.
3. Wang YXJ, De Baere, Idée JM, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015;27(2):96-121.
4. Van Malenstein H, Maleux G, Vandecaveye V, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011;34(7):368-76.

Before using refer to Instructions for Use for indications, contraindications, warnings, precautions, and directions for use.



Understand. Innovate. Deliver.™

Merit Medical Systems, Inc.
1600 West Merit Parkway
South Jordan, Utah 84095
1.801.253.1600
1.800.35.MERIT

Merit Medical Europe, Middle East, & Africa (EMEA)
Amerikalaan 42, 6199 AE Maastricht-Airport
The Netherlands
+31 43 358 82 22

Merit Medical Ireland Ltd.
Parkmore Business Park West
Galway, Ireland
+353 (0) 91 703 733

merit.com

Australia
+61 (0) 3 8373 4943

Austria
0800 295 374

Belgium
0800 72 906 (Dutch)
0800 73 172 (Français)

Brazil
+55 11 4561 - 0062

Canada
1.800.364.4370

China
+86-10 8561 0788

Denmark
80 88 00 24

Finland
0800 770 586

France
0800 91 60 30

Germany
0800 182 0871

Hong Kong
+852-2207 6888

India
+91-80-41223376

Ireland (Republic)
1800 553 163

Italy
800 897 005

Luxembourg
8002 25 22

Netherlands
0800 022 81 84

Norway
800 11629

Portugal
308 801 034

Russia
+7 495 221 89 02

Singapore
+65 67536311

South Korea
+8210 2205 0707

Spain
+34 911238406

Sweden
020 792 445

Switzerland
(Deutsch)
+41 22 518 02 30

(Français)
+41 22 518 02 52

(Italiano)
+41 22 518 00 35

UK
0800 973 115